In this real-world study, Kemin Li, Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China, and colleagues aimed to “study the correlation between BRCA mutation status and the risk of adverse reactions in patients with ovarian cancer.”

Dr Li and colleagues conducted this research on patients with ovarian cancer who were initially treated in the West China Second University Hospital of Sichuan University, the largest gynecological oncology center in western China.

Selected patients were treated with ovarian cancer between January 2016 and January 2020 at the West China Second University Hospital of Sichuan University and had their BRCA gene status evaluated.

Researchers used Multivariate Cox analysis to understand how BRCA mutation status and adverse reactions may correlate in patients with ovarian cancer during initial treatment.

Among the 349 participants, 79 (22.6%) patients had pathogenic BRCAvariants, of whom 57 (16.3%) had BRCA1variants and 22 (6.3%) had BRCA2variants. 

Dr Li and colleagues examined results from the Multivariate Cox analysis, and found that “pathogenic BRCAvariants were not related to the risk of adverse reactions, such as myelosuppression and allergies to chemotherapy drugs, during the initial treatment of ovarian cancer.”

“BRCAvariants did not increase the risk of adverse reactions, such as myelosuppression and allergies to chemotherapy drugs, in ovarian cancer patients during initial treatment,” concluded Dr Li and colleagues. 

Source: 

Li K, Yin R. BRCA variants and the risk of adverse reactions in patients with ovarian cancer: A single-center real-world study. Abstract presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago, IL, and virtual. Abstract e17530.